FDA sends update reminding of valproate and birth defects

12/4/2009 | Medscape (free registration)

The FDA issued a reminder to health care providers that valproate sodium, valproic acid and divalproex sodium are strongly linked to birth defects. The agency said clinicians should talk to women of childbearing age about the risks of the medications and consider alternative therapies.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
Washington DC, DC